NCT05410496 is a Phase 4 clinical trial of Tenofovir Alafenamide 25 MG in Safety Issues, sponsored by Taichung Veterans General Hospital.

Who is sponsoring NCT05410496?

NCT05410496 is sponsored by Taichung Veterans General Hospital.

What drugs are being tested in NCT05410496?

Interventions in NCT05410496: Tenofovir Alafenamide 25 MG.

What condition does NCT05410496 study?

NCT05410496 studies Safety Issues, Chronic Hepatitis B, Transplant Recipient.

Is NCT05410496 still recruiting?

NCT05410496 is currently active, enrolled. Last updated 9 January 2025.

Last reviewed 2025-01-09 · How we verify

NCT05410496

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tenofovir Alafenamide Switching Therapy in Kidney or Liver Transplant Recipients With Chronic HBV Infection

Active, enrolled Phase 4 Last updated 9 January 2025

What this trial tests

Phase 4 trial testing Tenofovir Alafenamide 25 MG in Safety Issues in 52 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

22 June 2021

Primary endpoint
30 July 2024

30 July 2027

Quick facts

Lead sponsor	Taichung Veterans General Hospital
Phase	Phase 4
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	52
Start date	22 June 2021
Primary completion	30 July 2024
Estimated completion	30 July 2027
Sites	2 locations across Taiwan

Drugs / interventions tested

Tenofovir Alafenamide 25 MG — full drug profile →

Conditions studied

Safety Issues — all drugs for Safety Issues →
Chronic Hepatitis B — all drugs for Chronic Hepatitis B →
Transplant Recipient — all drugs for Transplant Recipient →

Sponsor

Taichung Veterans General Hospital

Who can join

20 and older, any sex, with Safety Issues or Chronic Hepatitis B. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

tenofovir alafenamide (TAF) has been approved to be highly effective and safe in patients with chronic hepatitis B (CHB), therefore TAF may be a good option in kidney or liver transplant patients with chronic HBV infection. The aim of this prospective cohort study is to assess the safety, efficacy, and drug adherence improvement of TAF switching therapy in kidney or liver transplant patients with HBV infection.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Role of pharmacogenetics and tacrolimus dosing in liver transplantation.
Fung J. · · 2023 · cited 5× · PMID 36284080 · DOI 10.1007/s12072-022-10437-1

Verify or expand the search:

Other trials of Tenofovir Alafenamide 25 MG

Trials testing the same drug.

NCT05063071 — Tenofovir Alafenamide for HBV Prophylaxis in Post Orthotopic Liver Transplant · Phase 4 · unknown
NCT04201808 — Efficacy and Safety of TAF in Patients With Suboptimal Response to Other Nucleos(t)Ides · Phase 4 · unknown
NCT04703465 — Tenofovir Alafenamide for HBV Prophylaxis in HBV(-) Liver Transplant Recipients With HBcAb+ Donors · NA · unknown
NCT04507607 — Efficacy and Safety of TAF in Pregnant Women With Chronic Hepatitis B Infection · EARLY_PHASE1 · unknown
NCT04237376 — Chronic HBV Infection in Pregnant Women Taking TAF to Prevent Vertical Transmission · unknown

Other recruiting trials for Safety Issues

Currently open trials in the same condition.

NCT06485141 — BeSMART Secure Storage Counseling in the Inpatient Setting · NA · recruiting
NCT06494527 — A Phase 1 Study to Evaluate the Safety/Tolerability, PK/PD of RG002C0106 Injection in Healthy Adults · Phase 1 · active not recruiting
NCT06189170 — Phase I Study to Evaluate KP405 in Healthy and Parkinson's Disease Patients · EARLY_PHASE1 · recruiting
NCT06509490 — NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid Tumors · NA · recruiting
NCT06498167 — Active Pharmacovigilance Study of the Medicine Rinvoq™ (Upadacitinib) · recruiting

Other Taichung Veterans General Hospital trials

Trials by the same sponsor.

NCT06858436 — SGLT2 Inhibitor Utilization Re-perfusion Therapy · Phase 4 · not yet recruiting
NCT07453953 — A Comparison of Clinical Efficacy of Mytocel MSK With AMT and PRP Injections in Patients With Knee Osteoarthritis · EARLY_PHASE1 · not yet recruiting
NCT07487636 — 4DryField PH and Head and Neck Operations. · NA · enrolling by invitation
NCT07284017 — The Impact of Neuronavigation in rTMS for Hemiplegic Stroke Patients. · NA · not yet recruiting
NCT07363876 — The Efficacy of Ultrasonication in Combination With Corticosteroid Intraarticular Injection for Arthritis · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05410496 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Taichung Veterans General Hospital
Last refreshed: 9 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05410496.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing